Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CY-MET-RIC: PTCY and Methotrexate in RIC Allo-HSCT
NCT06252870Phase 2Recruiting
- Sponsor
- CHU de Nantes
- Start
- Jul 2024
- Primary completion
- Oct 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide, methotrexate in graft-versus-host disease (GVHD), hematologic malignancy, sponsored by CHU de Nantes. Started Jul 2024; status: recruiting.
02
Drugs
cyclophosphamidemethotrexate
03
Conditions
graft-versus-host disease (GVHD)hematologic malignancy
Beyond the preview
Go deeper on NCT06252870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06252870.